UPDATE: Goldman Sachs Maintains Buy On Amgen, Raises Target To $270, Adds To America's Conviction List Notes 'With the Enbrel litigation in the rear view mirror and the addition of Otezla we project 2020-2023 revenue/EPS growth of 4%/8%'